The potential lifelong consequences that weight-loss drugs could have on adolescents and children have a multidisciplinary team of clinicians, exercise and behavioral scientists, pharmacists, and ethics researchers at the University of California–Irvine (UCI) sounding alarms.
The team’s pre-proof paper (pdf), published by the Journal of Clinical and Translational Science, suggests that swapping traditional methods like diet and exercise to tackle childhood obesity and Type 2 diabetes for GLP-1RA medications like Wegovy and Ozempic will likely lead to a host of unintended physical and emotional problems.
